Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

10/4/24 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CLYM alert in real time by email

WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), announced today it will present and host investor meetings at William Blair's Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024.

About Climb Bio, Inc.

Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.

Investors

Chris Brinzey

ICR Westwicke

[email protected]

339-970-2843

Media

Jon Yu

ICR Westwicke

[email protected]

475-395-5375

Get the next $CLYM alert in real time by email

Introducing Nullity AI - Build Your AI Search Engine in 30 Seconds

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Chat with this insight

Recent Analyst Ratings for
$CLYM

$CLYM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Climb Bio Inc.

$CLYM
Leadership Updates

Live Leadership Updates

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

$CLYM
SEC Filings

SEC Form EFFECT filed by Climb Bio Inc.

SEC Form S-3 filed by Climb Bio Inc.

Climb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

$CLYM
Press Releases

Fastest customizable press release news feed in the world

Climb Bio to be Added to the Nasdaq Biotechnology Index

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

$CLYM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners initiated coverage on Climb Bio with a new price target

$CLYM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF ACCOUNTING OFFICER Pimblett Emily converted options into 5,000 shares and sold $2,495 worth of shares (1,235 units at $2.02), increasing direct ownership by 50% to 11,329 units (SEC Form 4)

SEC Form 4 filed by Director Williams Douglas E

SEC Form 3 filed by new insider Williams Douglas E

Introducing Nullity AI - Build Your AI Search Engine in 30 Seconds

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Chat with this insight

Recent Analyst Ratings for $CLYM

$CLYM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Climb Bio Inc.

$CLYM Leadership Updates

Live Leadership Updates

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

$CLYM SEC Filings

SEC Form EFFECT filed by Climb Bio Inc.

SEC Form S-3 filed by Climb Bio Inc.

Climb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

$CLYM Press Releases

Fastest customizable press release news feed in the world

Climb Bio to be Added to the Nasdaq Biotechnology Index

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

$CLYM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners initiated coverage on Climb Bio with a new price target

$CLYM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF ACCOUNTING OFFICER Pimblett Emily converted options into 5,000 shares and sold $2,495 worth of shares (1,235 units at $2.02), increasing direct ownership by 50% to 11,329 units (SEC Form 4)

SEC Form 4 filed by Director Williams Douglas E

SEC Form 3 filed by new insider Williams Douglas E

Recent Analyst Ratings for
$CLYM

$CLYM
Large Ownership Changes

$CLYM
Leadership Updates

$CLYM
SEC Filings

$CLYM
Press Releases

$CLYM
Analyst Ratings

$CLYM
Insider Trading